2025-12-21 - Analysis Report
Here's an analysis of Recursion Pharmaceuticals (RXRX) based on the data provided, broken down into sections.

**0) Simple Numbers First**

*   **Cumulative Return (RXRX):** -31.02%
*   **Cumulative Return (VOO):** 42.87%
*   **5-day SMA:** 4.36
*   **20-day SMA:** 4.50
*   **60-day SMA:** 5.02
*   **RSI:** 46.19
*   **PPO:** 0.06
*   **Market Risk Indicator (MRI):** 0.7
*   **Analyst Consensus:** Buy (~Hold)
*   **Target Price (Avg):** $7.00
*   **Last Close:** $4.26

**1) Return Rate Comparison and Alpha/Beta Analysis**

*   **Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company using artificial intelligence to discover, develop, and deliver medicines.
*   **Return Rate:** RXRX has significantly underperformed the S&P 500 (VOO) over the tracked period. Its cumulative return is -31.02% compared to VOO's 42.87%.
*   **Divergence:** The divergence is currently at -73.8, which is at the bottom 0.4% of the divergence range historically.
*   **Alpha/Beta Analysis:**

    *   The Alpha has decreased significantly in recent years, going from 26% in 2021-2023 to -54% in 2023-2025, indicating a sharp decline in performance compared to its benchmark.
    *   The Beta is near zero, meaning its price movement is weakly correlated with the broader market.
    *   CAGR is fluctuating between 11% and 22%
    *   MDD is very high (around 80%), indicating high risk
    *   Market cap has decreased significantly

**2) Recent Stock Price Fluctuations**

*   **Close Price:** $4.26 (down 4.05% from the previous close of $4.44)
*   **Moving Averages:** The stock price is trading below its 5-day, 20-day, and 60-day Simple Moving Averages (SMAs), which typically indicates a short-term downtrend. The 5-day SMA is less than the 20-day SMA, which is less than the 60-day SMA. The price seems to be declining quite rapidly.

**3) RSI, PPO, and Expected Return Analysis**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment). This suggests that according to the MRI, RXRX presents a moderate level of investment risk.
*   **RSI:** 46.19. This is a neutral RSI, not indicating that the stock is either overbought or oversold.
*   **PPO:** 0.06. The Percentage Price Oscillator suggests the short-term trend is similar to the long-term trend.
*   **Hybrid Signal:** The hybrid signal recommends a 100% buy with cash, suggesting that it would be a very safe decision.
*   **Recent Divergence Change:** A negative change of -4.7 in the 20-day relative divergence indicates a recent short-term decline.
*   **Expected Return:**  The significantly negative Expected Return (-540.8%) suggests a highly unfavorable long-term outlook based on the current model. This suggests that if invested, a dramatic underperformance compared to the S&P 500 is expected.

**4) Recent News & Significant Events**

The recent news headlines are largely positive:

*   **JPMorgan Upgrade:** Multiple articles highlight a recent upgrade of RXRX by J.P. Morgan, citing potential from their MEK inhibitor program and trial data. This is a significant positive catalyst.
*   **Clinical Trial Data:** There's mention of positive momentum in the REC-4881 trial data, suggesting progress in their drug development pipeline.
*   **Cramer's Comments:** Jim Cramer's comment that the stock is "so low that it comes in under the category of speculative" is a mixed bag. It acknowledges the risk but also implies potential upside if the company succeeds.
*   **Exscientia Merger:** Discussions and opinions on a potential merger indicate that there is market anticipation and speculation surrounding the company's future strategies and partnerships.

**4-2) Analyst Opinions**

*   **Consensus:** The analyst consensus is "Buy" with a mean rating of 2.50, suggesting a generally positive outlook, bordering on a "Hold" recommendation.
*   **Target Prices:** The average target price of $7.00 is significantly higher than the current price of $4.26, implying considerable upside potential if analysts' expectations are met.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue      |
| ---------- | ----- | ------------ |
| 2025-11-05 | -0.36 | $0.01 B     |
| 2025-08-05 | -0.41 | $0.02 B     |
| 2025-05-05 | -0.50 | $0.01 B     |
| 2024-11-06 | -0.34 | $0.03 B     |
| 2025-11-05 | -0.34 | $0.03 B     |

*   **Trend:**  Recursion Pharmaceuticals is not currently profitable, with consistent negative EPS. Revenue is fluctuating around small figures, but is not growing significantly.

**6) Financial Information**

| Quarter      | Revenue    | Profit Margin |
| ------------ | ---------- | ------------- |
| 2025-09-30   | $0.00B     | -194.74%      |
| 2025-06-30   | $0.02B     | -5.54%       |
| 2025-03-31   | $0.01B     | -47.31%      |
| 2024-12-31   | $0.00B     | -183.62%      |
| 2024-09-30   | $0.03B     | 53.69%       |

| Quarter      | Equity     | ROE      |
| ------------ | ---------- | -------- |
| 2025-09-30   | $1.05B     | -15.50%  |
| 2025-06-30   | $0.92B     | -18.70%  |
| 2025-03-31   | $0.93B     | -21.68%  |
| 2024-12-31   | $1.03B     | -17.29%  |
| 2024-09-30   | $0.52B     | -18.27%  |

*   **Revenue and Profitability:** The company's revenue generation is inconsistent, and its profitability has been erratic.  The high negative profit margins indicate substantial losses.
*   **Capital and Profitability:**  The company has significant equity, but negative ROE values indicate they are not generating profits from that equity.

**7) Comprehensive Analysis**

Recursion Pharmaceuticals (RXRX) presents a high-risk, high-reward investment opportunity.

*   **Negatives:** The stock has significantly underperformed the S&P 500. Its financial performance shows a lack of profitability and unstable revenue. Technical indicators suggest a recent downtrend. The highly negative expected return raises significant concerns.
*   **Positives:** Recent news indicates a positive catalyst with the J.P. Morgan upgrade and positive trial data momentum. The analyst consensus is a "Buy" with a significantly higher average target price, implying potential upside.
*   **Overall:** RXRX is a speculative investment. The company's reliance on future drug development success and ability to generate revenue makes it a gamble. The J.P. Morgan upgrade provides some hope, but the company needs to demonstrate tangible improvements in its financial performance and clinical trial outcomes to justify a long-term investment. The current "Buy" recommendation must be understood in the context of the stock's volatile history. Invest only if the company's future pans out as expected.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.